Benzinga | Nov 5, 2021 09:36AM EDT

Needham Maintains Buy on NeoGenomics, Lowers Price Target to $48

Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $55 to $48.